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Background: CLN3 disease is a disorder of lysosomal homeostasis predomi-
nantly affecting the retina and the brain. The severity of the underlying muta-
tions in CLN3 particularly determines onset and course of neurological
deterioration. Given the highly conserved start codon code among eukaryotic
species, we expected a variant in the start codon of CLN3 to give rise to the
classical, that is, severe, phenotype.
Case series: We present three patients with an identical CLN3 genotype (com-
pound heterozygosity for the common 1 kb deletion in combination with a
c.1A > C start codon variant) who all displayed a more attenuated phenotype
than expected. While their retinal phenotype was similar to as expected in clas-
sical CLN3 disease, their neurological phenotype was delayed. Two patients
had an early onset of cognitive impairment, but a particularly slow deteriora-
tion afterwards without any obvious motor impairment. The third patient also
had a late onset of cognitive impairment.
Conclusions: Contrasting our initial expectations, patients with a start codon
variant in CLN3 may display a protracted phenotype. Future work will have to
reveal the exact mechanism behind the assumed residual protein synthesis,
and determine whether this may be eligible to start codon targeted therapy.
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1 | INTRODUCTION
The start codon is responsible for the initiation of tran-
scription and errors herein are intuitively expected to
result in the absence of a functional protein.1 As pheno-
type correlates with genotype, a severe phenotype is
expected. In our clinic, we identified a patient with the
common 1 kb deletion and a c.1A > C start codon variant
in CLN3.2 CLN3 disease (OMIM #204200) is a neurode-
generative lysosomal storage disorder predominantly
affecting the retina and the brain. In the classical
phenotype—deriving from two truncating mutations
expected to completely abolish CLN3 protein synthesis—
neurodegeneration already starts and progresses in
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childhood limiting lifespan of patients to their late teens/
early 20s.2-4 Contrary to our expectations, the patient dis-
played a protracted phenotype—defined as deriving from
at least one “mild” (missense) mutation still allowing
some residual protein synthesis associated with a delayed
neurological phenotype.2 The milder phenotype could
not be explained by the 1 kb deletion on the other allele,
as this common founder mutation severely affects CLN3
protein synthesis generally hypothesized to completely
abolish CLN3 protein function.5,6 Indeed, although some
degree of phenotypic heterogeneity is seen, homozygosity
for the 1 kb deletion—present in around 75% of CLN3
disease patients—is consequently associated with the
classical phenotype.2,5,7,8
In this report, we assessed the hypothesis that the
c.1A > C variant in CLN3 is responsible for a protracted
CLN3 disease phenotype by successfully searching for
additional patients harboring this genotype and delineat-
ing their disease course.
2 | CASE SERIES
2.1 | Case 1
This 14-year-old boy is the only child born to unrelated,
Dutch parents. In his early childhood, a mild develop-
mental delay was noticed, particularly concerning behav-
ioral abnormalities, which led to the diagnosis of an
autism spectrum disorder. Around the age of 5 years, a
rapid decrease of vision was noticed and following oph-
thalmological examinations a cone-rod dystrophy was
identified. Due to the combination of a retinal dystrophy
with a mild developmental delay, the suspicion of CLN3
disease was raised. At the age of 6 years, the diagnosis of
CLN3 disease was confirmed based on compound hetero-
zygosity for the 1 kb deletion and a c.1A > C start codon
variant in CLN3. Ever since presentation, the patient has
remained essentially stable, without clear signs of cogni-
tive or motor deterioration. Regarding cognitive func-
tions, his total IQ (TIQ) of 71 around diagnosis at 6 years
of age has only declined to a verbal IQ (VIQ) of 67 at
12 years of age. Although TIQ and VIQ (at 12 years a TIQ
could no longer be assessed since the patient is
completely blind) are not directly interchangeable, this
does suggest some degree of cognitive stabilization. More
clearly, regarding motor function, this patient has walked
a near-normal, stable 6-minute walk test distance in the
past years - contrasting the early and continuous decline
seen in (classical) CLN3 disease4 (Figure 1). Recently, at
the age of 13 years, he has experienced his first general-
ized tonic-clonic seizure.
2.2 | Case 2
This woman, currently in her mid-twenties, was born to
unrelated, Dutch parents. Her younger sister and brother
are healthy. Of note, two far relatives had died due to
CLN3 disease. No further details, particularly no genetic
information, could be retrieved. Her early development
was reportedly normal. Around the age of 7 years a rapid
decrease in her vision was noticed. A retinal dystrophy
affecting the macula was found, which, in combination
with the suggested family history of CLN3 disease, led to
the identification of two compound heterozygous disease
causing variants in CLN3 (the 1 kb deletion + c.1A > C
start codon variant). Following the diagnosis of CLN3 dis-
ease, her parents were counseled on the expected disease
course in classical CLN3 disease. They therefore expected
that she would decline severely in the following years
resulting in premature death around 20 years of age. In
the following years however, psychomotor deterioration
was profoundly slower than expected. While she cur-
rently, at the age of 24, has exhibited some degree of
FIGURE 1 Six-minute walk test (6MWT) performance in a
patient with the 1.A > C start codon mutation in CLN3 compared
to classical CLN3 disease. Figure adjusted from Kuper et al.4 The
red dots show the 6MWT performance of case 1 indicating a stable,
near-normal, walking distance. This increasingly deviates from the
classical CLN3 disease decline as depicted by the black dots
(individual test results) and the blue line (overall velocity of the
6MWT distance decline over time). The grey area shows the 6MWT
reference values in healthy, sighted children (+/−2 SD)
SYNOPSIS
Counter-intuitively, a variant in the CLN3 start
codon may give rise to a protracted phenotype.
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deterioration, the deterioration is limited mainly con-
cerning short term memory, concentrating on multiple
tasks and word finding. She is still able to perform simple
tasks on a farm specialized in care for the mentally
handicapped. Similarly, and perhaps even more strikingly,
her motor function still seems preserved. She does not
experience any extrapyramidal symptoms: her speech is
still clear and she still walks independently without the
need for a wheelchair. Only since the age of 23 years, she
has started to suffer from generalized tonic-clonic
seizures.
2.3 | Case 3
This woman was the first child born to unrelated, Dutch
parents with a healthy younger sister. Following a nor-
mal early development, a rapid loss of vision was noticed
at the age of 7 years initially attributed to juvenile macu-
lar degeneration (Stargardt disease). However, after her
first generalized tonic-clonic seizure at 11 years of age
she was diagnosed with CLN3 disease based on a skin
biopsy and genetic analysis, although only one disease
causing variant (the common 1 kb deletion) could be
identified at that time. Despite the expected deterioration,
her cognitive and motoric abilities remained preserved
for years. With practical adjustments for her visual handi-
cap, she was able to follow regular level education and
even to graduate from high school at the age of 18 years
which has, to our knowledge, not been reported in classi-
cal CLN3 disease and which strongly implies an (above)
average IQ until her late teens. Around her final year at
high school, however, a decrease in her learning abilities
and short term memory became increasingly obvious. In
the following years, she quickly deteriorated both in her
cognitive and motoric abilities. From her early twenties
onwards, she lost the ability to walk and her speech
became unintelligible. She died just before the age of
26 years. After she passed away, carrier ship analysis
within the family led to the identification of the second
variant—the c.1A > C start codon variant—in CLN3.
3 | DISCUSSION
We report on three CLN3 disease patients compound het-
erozygous for the common 1 kb deletion and a c.1A > C
start codon variant in CLN3 who all displayed a pro-
tracted phenotype. The CLN3 protein is a transmem-
brane protein with yet unresolved function. In the
absence of a specific antibody (precluding reliable resid-
ual protein analysis) and/or an assay measuring residual
activity we focused on the clinical underpinning.9
Based on this milder clinical presentation, we hypoth-
esize that the c.1A > C variant in CLN3 does not
completely abolish CLN3 protein synthesis. Interestingly,
although start codon variants are often associated with a
severe disease course,10,11 there are several reports of dis-
ease causing start codon variants describing a milder phe-
notype.12-14 The residual protein synthesis in case of such
a start codon variant may be explained by the production
of a shorter but still partly functional protein because of
the use of an alternative downstream start codon, either
in the mutated transcript itself or in alternatively spliced
transcripts. The CLN3 protein is known to exist in multi-
ple isoforms, of which a few have a putative later start
position—recently extensively reviewed by Mirza et al6—
and thus do not encompass the mutated c.1A > C base
pair as present in our patients. Possibly, these unaffected
isoforms may provide the residual CLN3 protein produc-
tion allowing a protracted neurological phenotype. An
alternative hypothesis is that the mutated start codon
itself is still translated. From in vitro studies, non-AUG
translation initiation has been shown to occur in a wide
range of proteins, with some proteins even deriving solely
from a non-AUG start codon. Since non-AUG translation
initiation occurs at a much lower efficiency than the reg-
ular AUG translation initiation, this is probably one of
the processes to regulate protein expression. Of the non-
AUG start codons, the CUG alternative start codon—
which corresponds to the c.1A > C start codon variant in
our patients—has been suggested to provide the “least
inefficient” start codon.15 However, whether this tightly
controlled regulatory process also applies to a variant in
the start codon is speculative. In addition to transcrip-
tional (regulatory) processes as described above, also,
other—genetic, such as post-translational modifications,
and probably non-genetic—modifying factors could
impact residual CLN3 protein synthesis and function.6
Regardless of the exact underlying mechanism, the pro-
tracted phenotype displayed by all three patients dis-
cussed in this report strongly indicates that the c.1A > C
start codon variant in CLN3 allows some degree of resid-
ual protein synthesis.
Even with the start codon mutation being responsible
for some degree of residual protein synthesis, it remains
particularly puzzling why two of our patients displayed
early onset of cognitive impairment, but thereafter a par-
ticularly slow decline/long plateau phase contrasting case
3 who finished regular high school but thereafter declined
dramatically rapidly. Regarding the first two patients, par-
ticularly in light of (near) future therapeutic efficacy stud-
ies, prudence is warranted when classifying patients with
an atypical genotype as having classical CLN3 disease,
even if confirmed by an impaired IQ and motor score
(as in case 1) as they might still later display a protracted
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phenotype. Regarding the third patient, insight in the
chain of events that led the “neuronal” balance to collapse
so dramatically might also provide insight in neuronal
deterioration in CLN3 disease in general.
In humans, previous work has shed light on the fac-
tors that determine whether a start codon variant will
cause disease.16 Our work suggests that future work
should focus on the next step: the factors that determine
whether a disease causing start codon variant completely
abolishes protein synthesis or still allows some residual
protein synthesis and the mechanism behind this. Insight
herein will improve diagnosis, counseling, follow-up and
possibly even therapy development analogous to the con-
cept of nonsense codon read through.17,18
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